Insider Trading Signals — September 04, 2026 — After Hours — Last 12 Hours (Pacific Time)

Executive Summary

Insider activity over the past 12 hours is overwhelmingly skewed toward selling, with over 35 sale transactions recorded against a handful of purchases. Several high-profile C-suite executives — including the CEOs of Southern Company, Mirum Pharmaceuticals, Sprouts Farmers Market, and Arteris — offloaded significant positions, with individual transactions reaching into the millions. The lone bright spot on the buy side is a cluster of purchases at Smith Midland, where both the CEO and a director stepped up to acquire shares in meaningful size.

Activity Breakdown

Net Signal: 🔴 Bearish — Net selling of approximately $27.5M over the period.

Note: Purchase total includes First US Bancshares ($6.8K), Smith Midland CEO ($9.8K + $53.7K), Smith Midland director ($54.3K), Grove Collaborative ($5.5K), Columbia Financial ($233), Gaia ($1.7K), Horizon Kinetics/RENN Fund ($2.2K). Sale totals aggregated from all reported transactions.

Top Notable Transactions

🔴 Johnson & Johnson (JNJ) — Strong Bearish Signal

• Insider: Timothy Schmid, EVP & Worldwide Chairman of MedTech
• Transaction: Sale of $9.2M in company stock
• Signal: Strong Bearish
• Context: A $9.2M sale by a senior divisional chief at one of the world's largest healthcare companies is among the largest single transactions in this window and warrants close attention.

🔴 Astera Labs (ALAB) — Strong Bearish Signal

• Insider: Stefan Dyckerhoff, Director
• Transaction: Sale of $3.4M (12,499 shares)
• Signal: Strong Bearish
• Context: A director unloading $3.4M in a high-growth semiconductor connectivity company is a notable signal, particularly given ALAB's elevated valuation profile.

🔴 Mirum Pharmaceuticals (MIRM) — Strong Bearish Signal (Cluster)

• Insider: Christopher Peetz, CEO & Director + Jolanda Howe, SVP & Global Controller
• Transaction: CEO sold $2.96M (30,000 shares); Controller sold $65,800
• Signal: Strong Bearish
• Context: Two insiders selling simultaneously — including the CEO — at a specialty pharma company is a meaningful cluster signal.

🔴 Axsome Therapeutics (AXSM) — Strong Bearish Signal

• Insider: Mark Jacobson, COO
• Transaction: Sale of $2.08M (10,000 shares)
• Signal: Strong Bearish
• Context: A $2M+ COO sale at a clinical-stage biopharma is a high-conviction bearish signal worth monitoring.

🔴 Arteris (AIP) — Strong Bearish Signal

• Insider: K. Charles Janac, President, CEO, Director & 10% Owner
• Transaction: Sale of $2.07M (100,000 shares)
• Signal: Strong Bearish
• Context: When a CEO who is also a 10% owner sells $2M+ in a single transaction, it carries outsized weight relative to routine executive sales.

🔴 Sprouts Farmers Market (SFM) — Moderate Bearish Signal

• Insider: Jack Sinclair, CEO & Director
• Transaction: Sale of $1.7M (following option exercise)
• Signal: Moderate Bearish
• Context: Post-exercise sales are common, but a $1.7M CEO sale at a consumer staples retailer is still worth flagging given the size.

🔴 Aflac (AFL) — Strong Bearish Signal

• Insider: Japan Post Holdings Co., 10% Owner & Director
• Transaction: Sale of $1.58M (13,500 shares)
• Signal: Strong Bearish
• Context: A 10% owner reducing a position is one of the most significant bearish signals possible — this isn't a routine executive sale.

🔴 Leonardo DRS (DRS) — Moderate Bearish Signal

• Insider: Michael Dippold, EVP & CFO
• Transaction: Sale of $755K (20,317 shares)
• Signal: Moderate Bearish
• Context: A CFO selling $755K in a defense contractor is notable, particularly given the sector's elevated sentiment in recent years.

🔴 Itron (ITRI) — Moderate Bearish Signal

• Insider: Justin K. Patrick, SVP of Device Solutions
• Transaction: Sale of $994K
• Signal: Moderate Bearish
• Context: A near-$1M sale by a senior divisional VP at a smart infrastructure company is a meaningful data point.

🔴 AtriCure (ATRC) — Moderate Bearish Signal

• Insider: Salvatore Privitera, CTO
• Transaction: Sale of $407,557
• Signal: Moderate Bearish
• Context: A CTO sale approaching $410K at a medical device company signals potential caution at the technical leadership level.

🔴 Si-Bone (SIBN) — Moderate Bearish Signal

• Insider: Jeffrey Dunn, Director
• Transaction: Sale of $378,160 (20,000 shares)
• Signal: Moderate Bearish
• Context: A director selling 20,000 shares in a small-cap orthopedic device company is a notable position reduction.

🔴 Southern Company (SO) — Moderate Bearish Signal (Cluster)

• Insider: Peter Sena III, Chairman/President/CEO ($377,924) + Matthew Kim, Comptroller ($124,418)
• Transaction: Combined sales of ~$502K
• Signal: Moderate Bearish
• Context: Two insiders at a major utility selling on the same day is a mild cluster signal, though utility CEO sales are often planned.

🔴 Arista Networks (ANET) — Moderate Bearish Signal

• Insider: Chantelle Breithaupt, SVP & CFO
• Transaction: Sale of $119,811 (612 shares)
• Signal: Moderate Bearish
• Context: Even a relatively modest CFO sale at a high-multiple networking giant like Arista draws attention given the stock's premium valuation.

🟢 Smith Midland (SMID) — Strong Bullish Signal (Cluster)

• Insiders: Ashley B. Smith, CEO ($9,804 + $53,740) + Matthew I. Smith, Director ($54,300)
• Transaction: Combined purchases of ~$117,844
• Signal: Strong Bullish
• Context: Multiple insiders — including the CEO — buying in the open market at the same time is the strongest bullish cluster signal in this window.

🔴 Donegal Group (DGICA) — Mixed/Bearish Signal (Cluster)

• Insiders: Barry Huber, Director (sold $87,436) + Vincent Viozzi, SVP & CIO (sold $44,499) vs. Donegal Mutual Insurance Co. (acquired $381,768)
• Transaction: Net buying of ~$249,833 from the 10% owner; individual insiders selling
• Signal: Mixed — institutional 10% owner buying while individual insiders sell
• Context: The divergence between the controlling mutual company adding shares and individual insiders selling creates an ambiguous but watch-worthy signal.

Pattern Analysis

🔴 Cluster Selling — Mirum Pharmaceuticals (MIRM)
CEO Christopher Peetz ($2.96M) and Global Controller Jolanda Howe ($65,800) both sold shares in the same reporting window. Combined value: ~$3.03M. When the top executive and a financial controller reduce positions simultaneously, it is one of the more reliable bearish cluster signals in insider analysis.

🟢 Cluster Buying — Smith Midland (SMID)
CEO Ashley Smith made two separate purchases totaling ~$63,544, while director Matthew Smith added $54,300. Combined: ~$117,844. Open-market purchases by both the CEO and a director at a small-cap company represent genuine conviction — insiders rarely buy unless they believe the stock is undervalued.

🔴 Mixed Cluster — Donegal Group (DGICA)
Three separate filings: the 10% owner (Donegal Mutual Insurance Co.) bought $381,768 while director Barry Huber sold $87,436 and SVP Vincent Viozzi sold $44,499. The controlling entity accumulating while individuals reduce is an ambiguous signal — worth monitoring for resolution.

🔴 Sector Pattern — Healthcare/Biopharma Selling
Multiple healthcare and biopharma insiders sold in this window: J&J ($9.2M), Axsome Therapeutics ($2.08M), Mirum Pharmaceuticals ($3.03M combined), AtriCure ($407K), Artivion ($216K), Septerna ($126K), 4D Molecular Therapeutics ($8.2K), ResMed ($227K). The breadth of selling across healthcare subsectors — MedTech, biopharma, medical devices — is a notable sector-wide pattern.

🔴 Sector Pattern — Technology Selling
Astera Labs ($3.4M), Itron ($994K), Arista Networks ($120K), C3.ai ($174K) all saw insider sales. While some (C3.ai) were flagged as tax-related, the aggregate tech selling pressure is meaningful.

🔴 Timing Note — Post-Labor Day Window
The concentration of filings on September 4, 2026 (the day after Labor Day weekend) likely reflects a backlog of transactions executed September 1–3 being reported simultaneously. This compresses the apparent selling into a single window and may slightly overstate the bearish signal for any single day.

Sector Breakdown

Healthcare / Biopharma / Medical Devices 🔴 (Strong Bearish)

• Net Signal: ~$16M+ in net selling
• Notable: JNJ, AXSM, MIRM, ATRC, AORT, RMD, SEPN, FDMT
• Context: The broadest and most dollar-heavy selling sector in this window, spanning MedTech giants to small-cap biotechs — a notable sector-wide insider distribution signal.

Technology / Semiconductors 🔴 (Bearish)

• Net Signal: ~$4.7M in net selling
• Notable: ALAB, ITRI, ANET, AI (C3.ai)
• Context: High-multiple tech names seeing insider distribution, with Astera Labs' $3.4M director sale the standout.

Consumer / Retail 🔴 (Moderate Bearish)

• Net Signal: ~$2M in net selling
• Notable: SFM (Sprouts), FNKO (Funko)
• Context: CEO and CFO-level sales at two consumer-facing companies suggest some caution in the sector.

Utilities 🔴 (Moderate Bearish)

• Net Signal: ~$502K in net selling
• Notable: SO (Southern Company)
• Context: CEO and comptroller selling at a major utility; planned sales are common but the cluster element adds weight.

Insurance / Financial Services 🟡 (Mixed)

• Net Signal: Mixed — DGICA buying ($381K) vs. selling ($131K); AFL selling ($1.58M)
• Notable: AFL, DGICA, ASB, AMAL
• Context: Aflac's 10% owner sale is the dominant signal; Donegal's institutional buyer partially offsets individual selling.

Industrials / Defense 🔴 (Moderate Bearish)

• Net Signal: ~$1.1M in net selling
• Notable: DRS (Leonardo DRS), TILE (Interface)
• Context: CFO-level selling at a defense contractor and a director sale at a flooring manufacturer.

Small-Cap / Micro-Cap 🟢 (Bullish — isolated)

• Net Signal: ~$118K net buying
• Notable: SMID (Smith Midland), FUSB (First US Bancshares), GROV (Grove Collaborative), GAIA
• Context: The only genuine buying conviction in this window is concentrated in small and micro-cap names — a common pattern where insiders have more direct knowledge of undervaluation.

Market Implications

The overwhelming tilt toward selling in this window — roughly $27.5M net — sends a cautious signal about near-term insider sentiment. However, context matters: post-holiday filing backlogs, pre-planned 10b5-1 sales, and tax-driven transactions (explicitly noted in C3.ai's case) can inflate apparent selling volume. That said, the sheer breadth of selling across healthcare, technology, and consumer sectors — with multiple C-suite executives participating — is difficult to dismiss entirely.

The healthcare sector deserves particular attention. When insiders at companies ranging from J&J (a Dow component) to small-cap biotechs are all reducing exposure in the same 12-hour window, it may reflect sector-specific concerns — whether regulatory, pricing, or valuation-related. The Mirum Pharmaceuticals cluster (CEO + controller selling simultaneously) is the most actionable signal in this group.

The one genuinely bullish signal — Smith Midland's CEO and director both buying in the open market — stands out precisely because it runs against the tide. Open-market purchases, especially by a CEO, are among the most reliable bullish signals in insider analysis. While SMID is a micro-cap with limited liquidity, the conviction shown here is worth noting for investors already tracking the name.

Key Takeaways

• 🔴 J&J (JNJ) — A $9.2M sale by the MedTech division chief is the single largest transaction in this window and the most significant bearish signal by dollar value.
• 🔴 Mirum Pharmaceuticals (MIRM) — CEO + Controller selling simultaneously ($3M+ combined) is the strongest bearish cluster signal of the session.
• 🔴 Astera Labs (ALAB) — A $3.4M director sale at a high-growth semiconductor name warrants close monitoring given valuation sensitivity.
• 🔴 Axsome Therapeutics (AXSM) — COO selling $2.08M in a clinical biopharma is a high-conviction bearish data point.
• 🔴 Arteris (AIP) — CEO + 10% owner selling $2.07M is doubly significant; controlling shareholders rarely reduce without reason.
• 🔴 Aflac (AFL) — Japan Post Holdings (10% owner) selling $1.58M is among the most structurally significant signals — 10% owner sales are rare and meaningful.
• 🟢 Smith Midland (SMID) — The only genuine bullish cluster: CEO and director both buying open-market (~$118K combined) signals real conviction in a micro-cap.
• 🟡 Donegal Group (DGICA) — Divergence between the controlling mutual company buying ($382K) and individual insiders selling ($132K) creates an ambiguous but watch-worthy signal.
• 🔴 Southern Company (SO) — CEO + Comptroller selling ~$502K combined on the same day is a mild cluster signal at a major utility.
• 🔴 Healthcare sector broadly — Eight separate healthcare/biopharma/device companies saw insider selling; the sector-wide breadth is the most notable pattern of the session.
• 🔴 Technology sector — Astera Labs, Itron, Arista Networks, and C3.ai all saw insider sales; high-multiple tech names facing distribution pressure.
• 🔴 Buying-to-selling ratio — Approximately 8 purchases vs. 36 sales; a 4.5:1 sell ratio by count and ~200:1 by dollar value — unambiguously bearish in aggregate.
• 🟡 Post-holiday filing effect — Many transactions dated September 1–3 were filed today; the apparent concentration of selling may partly reflect a reporting backlog rather than a single-day sentiment shift.
• 🔴 Leonardo DRS (DRS) — CFO selling $755K in a defense contractor is notable given the sector's elevated profile.
• 🟢 Small-cap buying — The only buying conviction is concentrated in micro/small-caps (SMID, FUSB, GROV, GAIA) — a pattern consistent with insiders having clearer visibility into undervaluation at smaller companies.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Insider transactions can have many motivations beyond stock outlook.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/